ID   ADR1_CAEEL              Reviewed;         964 AA.
AC   Q9U3D6; G5EF17; G5EG30; Q86GC2; Q86GC3; Q8I8G9; Q8I8H0; Q8I8H1;
DT   31-JAN-2018, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 2.
DT   07-APR-2021, entry version 133.
DE   RecName: Full=A-to-I RNA editing regulator adr-1 {ECO:0000305};
GN   Name=adr-1 {ECO:0000312|WormBase:H15N14.1c};
GN   ORFNames=H15N14.1 {ECO:0000312|WormBase:H15N14.1c};
OS   Caenorhabditis elegans.
OC   Eukaryota; Metazoa; Ecdysozoa; Nematoda; Chromadorea; Rhabditida;
OC   Rhabditina; Rhabditomorpha; Rhabditoidea; Rhabditidae; Peloderinae;
OC   Caenorhabditis.
OX   NCBI_TaxID=6239 {ECO:0000312|Proteomes:UP000001940};
RN   [1] {ECO:0000312|EMBL:AAN61049.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS C; D; E; F AND G), FUNCTION, AND
RP   TISSUE SPECIFICITY.
RC   STRAIN=Bristol N2 {ECO:0000312|EMBL:AAN61049.1};
RX   PubMed=12426375; DOI=10.1093/emboj/cdf607;
RA   Tonkin L.A., Saccomanno L., Morse D.P., Brodigan T., Krause M., Bass B.L.;
RT   "RNA editing by ADARs is important for normal behavior in Caenorhabditis
RT   elegans.";
RL   EMBO J. 21:6025-6035(2002).
RN   [2] {ECO:0000312|Proteomes:UP000001940}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Bristol N2 {ECO:0000312|Proteomes:UP000001940};
RX   PubMed=9851916; DOI=10.1126/science.282.5396.2012;
RG   The C. elegans sequencing consortium;
RT   "Genome sequence of the nematode C. elegans: a platform for investigating
RT   biology.";
RL   Science 282:2012-2018(1998).
RN   [3] {ECO:0000305}
RP   FUNCTION, AND ROLE IN TRANSGENE SILENCING.
RX   PubMed=12419225; DOI=10.1016/s1097-2765(02)00649-4;
RA   Knight S.W., Bass B.L.;
RT   "The role of RNA editing by ADARs in RNAi.";
RL   Mol. Cell 10:809-817(2002).
RN   [4] {ECO:0000305}
RP   FUNCTION.
RX   PubMed=14657490; DOI=10.1126/science.1091340;
RA   Tonkin L.A., Bass B.L.;
RT   "Mutations in RNAi rescue aberrant chemotaxis of ADAR mutants.";
RL   Science 302:1725-1725(2003).
RN   [5] {ECO:0000305}
RP   SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.
RX   PubMed=18719245; DOI=10.1261/rna.1165008;
RA   Hundley H.A., Krauchuk A.A., Bass B.L.;
RT   "C. elegans and H. sapiens mRNAs with edited 3' UTRs are present on
RT   polysomes.";
RL   RNA 14:2050-2060(2008).
RN   [6] {ECO:0000305}
RP   FUNCTION.
RX   PubMed=20011587; DOI=10.1371/journal.pone.0008210;
RA   Sebastiani P., Montano M., Puca A., Solovieff N., Kojima T., Wang M.C.,
RA   Melista E., Meltzer M., Fischer S.E., Andersen S., Hartley S.H.,
RA   Sedgewick A., Arai Y., Bergman A., Barzilai N., Terry D.F., Riva A.,
RA   Anselmi C.V., Malovini A., Kitamoto A., Sawabe M., Arai T., Gondo Y.,
RA   Steinberg M.H., Hirose N., Atzmon G., Ruvkun G., Baldwin C.T., Perls T.T.;
RT   "RNA editing genes associated with extreme old age in humans and with
RT   lifespan in C. elegans.";
RL   PLoS ONE 4:E8210-E8210(2009).
RN   [7] {ECO:0000305}
RP   FUNCTION, INTERACTION WITH ADR-2, AND MUTAGENESIS OF 223-LYS--LYS-227 AND
RP   584-LYS--LYS-588.
RX   PubMed=24508457; DOI=10.1016/j.celrep.2014.01.011;
RA   Washburn M.C., Kakaradov B., Sundararaman B., Wheeler E., Hoon S.,
RA   Yeo G.W., Hundley H.A.;
RT   "The dsRBP and inactive editor ADR-1 utilizes dsRNA binding to regulate A-
RT   to-I RNA editing across the C. elegans transcriptome.";
RL   Cell Rep. 6:599-607(2014).
RN   [8] {ECO:0000305}
RP   FUNCTION.
RX   PubMed=25373143; DOI=10.1101/gr.176107.114;
RA   Zhao H.Q., Zhang P., Gao H., He X., Dou Y., Huang A.Y., Liu X.M., Ye A.Y.,
RA   Dong M.Q., Wei L.;
RT   "Profiling the RNA editomes of wild-type C. elegans and ADAR mutants.";
RL   Genome Res. 25:66-75(2015).
RN   [9] {ECO:0000305}
RP   FUNCTION.
RX   PubMed=26917557; DOI=10.1261/rna.055079.115;
RA   Washburn M.C., Hundley H.A.;
RT   "Trans and cis factors affecting A-to-I RNA editing efficiency of a
RT   noncoding editing target in C. elegans.";
RL   RNA 22:722-728(2016).
RN   [10] {ECO:0000305}
RP   FUNCTION.
RX   PubMed=28925356; DOI=10.7554/elife.28625;
RA   Deffit S.N., Yee B.A., Manning A.C., Rajendren S., Vadlamani P.,
RA   Wheeler E.C., Domissy A., Washburn M.C., Yeo G.W., Hundley H.A.;
RT   "The C. elegans neural editome reveals an ADAR target mRNA required for
RT   proper chemotaxis.";
RL   Elife 6:0-0(2017).
CC   -!- FUNCTION: Required for the hydrolytic deamination of adenosine to
CC       inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA
CC       editing (PubMed:12426375). Does not have deaminase activity but binds
CC       to dsRNA and regulates A-to-I RNA editing, possibly by modulating the
CC       accessibility of the double-stranded RNA-specific adenosine deaminase
CC       adr-2 for target adenosines (PubMed:24508457, PubMed:25373143).
CC       Regulates editing efficiency of specific adenosines in 3' untranslated
CC       regions of target mRNAs (PubMed:24508457). Represses editing efficiency
CC       of the Y75B8A.8 3' UTR in neurons (PubMed:26917557). Required for
CC       correct expression and A-to-I editing of clec-41 (PubMed:28925356).
CC       Required for normal chemotaxis (PubMed:12426375, PubMed:14657490). Also
CC       required for normal vulva development (PubMed:12426375). Plays a role
CC       in determining lifespan (PubMed:20011587, PubMed:25373143). Not
CC       required for RNA interference (PubMed:12419225). Likely to play a role
CC       in determining whether a dsRNA enters the RNAi pathway
CC       (PubMed:14657490). {ECO:0000269|PubMed:12419225,
CC       ECO:0000269|PubMed:12426375, ECO:0000269|PubMed:14657490,
CC       ECO:0000269|PubMed:20011587, ECO:0000269|PubMed:24508457,
CC       ECO:0000269|PubMed:25373143, ECO:0000269|PubMed:26917557,
CC       ECO:0000269|PubMed:28925356}.
CC   -!- SUBUNIT: Interacts with double-stranded RNA-specific adenosine
CC       deaminase adr-2. {ECO:0000269|PubMed:24508457}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:18719245}. Cytoplasm
CC       {ECO:0000269|PubMed:18719245}. Note=Detected both in the nuclear
CC       fraction and in the ribosome-containing pellet of the cytoplasm.
CC       {ECO:0000269|PubMed:18719245}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=c {ECO:0000303|PubMed:12426375};
CC         IsoId=Q9U3D6-1; Sequence=Displayed;
CC       Name=d {ECO:0000303|PubMed:12426375};
CC         IsoId=Q9U3D6-2; Sequence=VSP_059300, VSP_059305, VSP_059306,
CC                                  VSP_059307;
CC       Name=e {ECO:0000303|PubMed:12426375};
CC         IsoId=Q9U3D6-3; Sequence=VSP_059300, VSP_059305, VSP_059306;
CC       Name=f {ECO:0000303|PubMed:12426375};
CC         IsoId=Q9U3D6-4; Sequence=VSP_059301, VSP_059302;
CC       Name=g {ECO:0000303|PubMed:12426375};
CC         IsoId=Q9U3D6-5; Sequence=VSP_059303, VSP_059304;
CC   -!- TISSUE SPECIFICITY: Expression begins early in embryogenesis where it
CC       is detected in late gastrula and comma stage embryos. By the comma
CC       stage, expression is highest in developing neuronal tissue in the head,
CC       tail and ventral side. Neuronal expression continues through
CC       embryogenesis and, by the L1 larval stage, is the prominent pattern.
CC       Expressed in most, if not all, cells of the nervous system at all
CC       larval stages and in adult animals. Also expressed in the developing
CC       vulva but not expressed in the adult vulva.
CC       {ECO:0000269|PubMed:12426375}.
CC   -!- DEVELOPMENTAL STAGE: Highest expression observed in the embryo. Levels
CC       decrease dramatically after embryogenesis, remain relatively constant
CC       during larval stages and increase again at the onset of adulthood.
CC       {ECO:0000269|PubMed:18719245}.
CC   -!- MISCELLANEOUS: Can prevent somatic transgenes from inducing gene
CC       silencing via the RNA interference pathway. This may occur due to A-to-
CC       I editing of transgene-derived dsRNA, preventing transgene RNAi.
CC       {ECO:0000269|PubMed:12419225}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY150815; AAN61049.1; -; mRNA.
DR   EMBL; AY150816; AAN61050.1; -; mRNA.
DR   EMBL; AY150817; AAN61051.1; -; mRNA.
DR   EMBL; AY150818; AAN61052.1; -; mRNA.
DR   EMBL; AY150819; AAN61053.1; -; mRNA.
DR   EMBL; BX284601; CAB09530.2; -; Genomic_DNA.
DR   EMBL; BX284601; CAD60417.1; -; Genomic_DNA.
DR   EMBL; BX284601; CAD60418.1; -; Genomic_DNA.
DR   EMBL; BX284601; CAD60419.1; -; Genomic_DNA.
DR   EMBL; BX284601; CAD60420.1; -; Genomic_DNA.
DR   PIR; T23095; T23095.
DR   RefSeq; NP_492153.2; NM_059752.5. [Q9U3D6-1]
DR   RefSeq; NP_492154.2; NM_059753.5. [Q9U3D6-2]
DR   RefSeq; NP_871801.1; NM_182001.3. [Q9U3D6-3]
DR   RefSeq; NP_871802.1; NM_182002.3.
DR   RefSeq; NP_871803.1; NM_182003.3. [Q9U3D6-5]
DR   SMR; Q9U3D6; -.
DR   STRING; 6239.H15N14.1c; -.
DR   EPD; Q9U3D6; -.
DR   PaxDb; Q9U3D6; -.
DR   PeptideAtlas; Q9U3D6; -.
DR   EnsemblMetazoa; H15N14.1c.1; H15N14.1c.1; WBGene00000079. [Q9U3D6-1]
DR   EnsemblMetazoa; H15N14.1d.1; H15N14.1d.1; WBGene00000079. [Q9U3D6-2]
DR   EnsemblMetazoa; H15N14.1e.1; H15N14.1e.1; WBGene00000079. [Q9U3D6-3]
DR   EnsemblMetazoa; H15N14.1f.1; H15N14.1f.1; WBGene00000079. [Q9U3D6-4]
DR   EnsemblMetazoa; H15N14.1g.1; H15N14.1g.1; WBGene00000079. [Q9U3D6-5]
DR   GeneID; 172542; -.
DR   KEGG; cel:CELE_H15N14.1; -.
DR   UCSC; H15N14.1c; c. elegans.
DR   CTD; 172542; -.
DR   WormBase; H15N14.1c; CE32459; WBGene00000079; adr-1. [Q9U3D6-1]
DR   WormBase; H15N14.1d; CE33125; WBGene00000079; adr-1. [Q9U3D6-2]
DR   WormBase; H15N14.1e; CE33126; WBGene00000079; adr-1. [Q9U3D6-3]
DR   WormBase; H15N14.1f; CE33127; WBGene00000079; adr-1. [Q9U3D6-4]
DR   WormBase; H15N14.1g; CE33128; WBGene00000079; adr-1. [Q9U3D6-5]
DR   eggNOG; KOG2777; Eukaryota.
DR   GeneTree; ENSGT00940000157942; -.
DR   InParanoid; Q9U3D6; -.
DR   OMA; AKQKCAE; -.
DR   OrthoDB; 578137at2759; -.
DR   Reactome; R-CEL-75102; C6 deamination of adenosine.
DR   Reactome; R-CEL-77042; Formation of editosomes by ADAR proteins.
DR   PRO; PR:Q9U3D6; -.
DR   Proteomes; UP000001940; Chromosome I.
DR   Bgee; WBGene00000079; Expressed in multi-cellular organism and 3 other tissues.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0022626; C:cytosolic ribosome; IDA:WormBase.
DR   GO; GO:0005730; C:nucleolus; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IDA:WormBase.
DR   GO; GO:0003725; F:double-stranded RNA binding; IBA:GO_Central.
DR   GO; GO:0003729; F:mRNA binding; IDA:UniProtKB.
DR   GO; GO:0008251; F:tRNA-specific adenosine deaminase activity; IBA:GO_Central.
DR   GO; GO:0006382; P:adenosine to inosine editing; IMP:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; IEA:UniProtKB-KW.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:UniProtKB.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; IMP:UniProtKB.
DR   GO; GO:0040028; P:regulation of vulval development; IMP:UniProtKB.
DR   GO; GO:0006396; P:RNA processing; IBA:GO_Central.
DR   InterPro; IPR002466; A_deamin.
DR   InterPro; IPR014720; dsRBD_dom.
DR   Pfam; PF02137; A_deamin; 1.
DR   Pfam; PF00035; dsrm; 2.
DR   SMART; SM00552; ADEAMc; 1.
DR   SMART; SM00358; DSRM; 2.
DR   PROSITE; PS50141; A_DEAMIN_EDITASE; 1.
DR   PROSITE; PS50137; DS_RBD; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Chemotaxis; Cytoplasm; mRNA processing; Nucleus;
KW   Reference proteome; RNA-binding.
FT   CHAIN           1..964
FT                   /note="A-to-I RNA editing regulator adr-1"
FT                   /id="PRO_0000442984"
FT   DOMAIN          179..240
FT                   /note="DRBM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00266"
FT   DOMAIN          527..601
FT                   /note="DRBM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00266"
FT   DOMAIN          670..953
FT                   /note="A to I editase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00240"
FT   COMPBIAS        51..99
FT                   /note="Gln-rich"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00006"
FT   VAR_SEQ         95..160
FT                   /note="Missing (in isoform d and isoform e)"
FT                   /evidence="ECO:0000269|PubMed:12426375"
FT                   /id="VSP_059300"
FT   VAR_SEQ         95..100
FT                   /note="KYGQQG -> VYLFLI (in isoform f)"
FT                   /evidence="ECO:0000269|PubMed:12426375"
FT                   /id="VSP_059301"
FT   VAR_SEQ         101..964
FT                   /note="Missing (in isoform f)"
FT                   /evidence="ECO:0000269|PubMed:12426375"
FT                   /id="VSP_059302"
FT   VAR_SEQ         114..115
FT                   /note="GA -> AK (in isoform g)"
FT                   /evidence="ECO:0000269|PubMed:12426375"
FT                   /id="VSP_059303"
FT   VAR_SEQ         116..964
FT                   /note="Missing (in isoform g)"
FT                   /evidence="ECO:0000269|PubMed:12426375"
FT                   /id="VSP_059304"
FT   VAR_SEQ         277..279
FT                   /note="Missing (in isoform d and isoform e)"
FT                   /evidence="ECO:0000269|PubMed:12426375"
FT                   /id="VSP_059305"
FT   VAR_SEQ         300..301
FT                   /note="Missing (in isoform d and isoform e)"
FT                   /evidence="ECO:0000269|PubMed:12426375"
FT                   /id="VSP_059306"
FT   VAR_SEQ         938
FT                   /note="K -> KVGVLFSSFLRLLLHNINFQ (in isoform d)"
FT                   /evidence="ECO:0000269|PubMed:12426375"
FT                   /id="VSP_059307"
FT   MUTAGEN         223..227
FT                   /note="KKAAK->EAAAA: Defective mRNA binding, A-to-I editing
FT                   and interaction with adr-2; when associated with 584-E--A-
FT                   588."
FT                   /evidence="ECO:0000269|PubMed:24508457"
FT   MUTAGEN         584..588
FT                   /note="KKLAK->EAAAA: Defective mRNA binding, A-to-I editing
FT                   and interaction with adr-2; when associated with 223-E--A-
FT                   227."
FT                   /evidence="ECO:0000269|PubMed:24508457"
FT   CONFLICT        152
FT                   /note="F -> L (in Ref. 1; AAN61049)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        285
FT                   /note="N -> H (in Ref. 1; AAN61049)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        387
FT                   /note="T -> A (in Ref. 1; AAN61050)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        472
FT                   /note="C -> Y (in Ref. 1; AAN61049)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        635
FT                   /note="C -> R (in Ref. 1; AAN61049)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        671
FT                   /note="M -> V (in Ref. 1; AAN61051)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        749
FT                   /note="C -> R (in Ref. 1; AAN61049)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        756
FT                   /note="A -> V (in Ref. 1; AAN61050)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        803
FT                   /note="L -> M (in Ref. 1; AAN61049)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        809
FT                   /note="L -> P (in Ref. 1; AAN61050)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        834
FT                   /note="S -> P (in Ref. 1; AAN61050)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        834
FT                   /note="S -> T (in Ref. 1; AAN61051)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   964 AA;  107427 MW;  2CE3A400BBE7AAB8 CRC64;
     MDQNPNYNFG YGQAYGSGTD HTSDSTNNYN WASQWSQPES AASLATHTFP QYVSQQQQQQ
     QQQAQQQAQN TYAAMNPIST FMQQQQRAQT FPQKKYGQQG GAPKPSAIRN NNFGAFGGGH
     ALSQEWVQPM SQNQMGGPQG NRFFNNQKGG PFNQNKPNWR QNKPKGPAAP KKFDSTGKSP
     AMLLHELFKD VSEEYTEVEG VPKKYCCTLK VNGRTFQMES VNKKAAKQKC SELVVRDLRP
     DVHVTPFEEG VAAKAAAPVK KEIDAASGNG QNNKRNLLQA DAISNQPTPK KVSAVKKAKL
     QLTPVESALS LLDLMQKIIA ESAEKYSPVF EASEVPKDPE IPEVEVKKEE VDTNGENVAN
     EKKSGWRKNE TMHNVTLKFV EQNKQYTKMG PSRGVLKDMV IREALRDLFN VSHADITTVA
     RRHASNRLGH DTTILQCLNT ICSILNCTLT IECEPAEDRP LGIGRAYFMA KCTIIDHNEN
     DLKFEVKSSS LASKAMAKDW VAQETLKNYF AIDPSSCVKT DAVSSQGPCA LLHAMLNKQT
     KQKCKIAYEF KDNVPPVAGQ ATTTFYCECV IDETDRYIGV GRSKKLAKSE AAMQALKKLF
     KIDYDPAGNY PLALTSRAMT ESKVSPLCRH IAEFCKREYH QMTEYYQIPP SNLFAAFLLV
     NAQEEKRVLA MGSSIQYIVE PDTLSGANGT SLLHLDAIIL ARRAMLKAFI HELSTVDSEC
     SIFEKKEEGK AALKPNLRLV LYSNYSPPCI HAVDDAATKK LSYVTPTNLT CVPDDVLTYE
     QIKETKSLRV HCTADKLFKW NTLGIQGALL SNVLHPIFID NIFFGSEAPV SDESLSYALQ
     GRLGPNENER EIIVESMPVQ MRMHMGISHL WHRGVDSVET LDYNTGRTSK GSPSRVCKAE
     IFEAYRKLNG VDQAVVNYAK AKEMASEYQY EKKVFYEKLE AAGLGKWQTK PAELVDSFTL
     AAFD
//
